Psoriasis is a multifactorial immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2-3% of the worldwide population. Psoriasis involves skin, joints, or both, and it is associated with several comorbidities, including metabolic, rheumatological, cardiovascular, psychiatric complications, and other chronic inflammatory diseases, which are the expression of the complex underlying pathogenetic mechanism. An accurate characterization of the immune pathways involved in psoriasis led to recognize the new molecules, (IL)17 and 23, which become the new target of biologic therapy for moderate-to-severe plaque psoriasis.
Novel Therapeutic Approaches and Targets for Treatment of Psoriasis / Radi, Giulia; Campanati, Anna; Diotallevi, Federico; Bianchelli, Tommaso; Offidani, Annamaria. - In: CURRENT PHARMACEUTICAL BIOTECHNOLOGY. - ISSN 1873-4316. - ELETTRONICO. - 22:1(2021), p. 7-31. [10.2174/1389201021666200629150231]